This drug is a hypoglycemic sulfonylurea-oral diabetes treatment drug. Gliclazide lowers blood sugar levels by stimulating pancreatic β cells to secrete insulin. For type 2 diabetes, gliclazide can restore the first-phase insulin secretion peak in response to glucose and increase the second-phase insulin secretion. It can be seen that the insulin secretion response induced or stimulated by glucose after a meal is significantly increased.

It changes the signal transmission of the central nervous system, has an stimulatory effect on dopamine receptors and 5-hydroxytryptamine receptors, and a blocking effect on α-adrenergic receptors; it improves the damaged brain metabolic function and reflects the changes in brain electrical activity (especially in the EEG spectrum); it shortens the cerebral circulation time; it improves age-related symptoms of intellectual decline (such as self-care, social behavior, emotional state and intellectual behavior); it stabilizes cerebral vascular tension and has a preventive effect on migraine.

In vitro, it has an inhibitory effect on herpes simplex virus, varicella zoster virus, cytomegalovirus, etc. The drug is easily taken up by herpes simplex virus, then phosphorylated into triphosphate, which inhibits viral replication in two ways: interfering with viral DNA polymerase and inhibiting viral replication; under the action of DNA polymerase, it binds to the growing DNA chain, causing the extension of the DNA chain to be interrupted.

Extract from the above information